Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis (Q36577467)

15 August 2017

1 reference

title

Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis (English)

1 reference

15 August 2017

Cailin Henderson

1

1 reference

15 August 2017

John C Davis

series ordinal

2

1 reference

15 August 2017

publication date

1 April 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

211-218

1 reference

HLA-B27 and genetic predisposing factors in spondyloarthropathies

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Spondyloarthritis: update on pathogenesis and management

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Signal transduction by tumor necrosis factor and its relatives

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Bone mineral density improvement in spondyloarthropathy after treatment with etanercept

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

The incidence and management of infusion reactions to infliximab: a large center experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Tuberculosis in the cytokine era: what rheumatologists need to know

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Anti-TNF-alpha-induced systemic lupus syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0157

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0157

1 reference

15 August 2017

1 reference